Scopus Biopharma Overview
Valuation check: SCPS's ROE is 92.0%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow92.00%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SCPS is 92.0%. That is above the Healthcare sector average of 20.86%. Investors often review this figure alongside Scopus Biopharma's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, SCPS currently prints 92.0% for ROE, while the sector average sits near 20.86%. That is roughly 341.1% above the sector mean. Large gaps often invite a closer look at Scopus Biopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Scopus Biopharma converts resources into returns. At 92.0%, SCPS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SCPS's ROE (92.0%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Scopus Biopharma's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
